SGLT2 Inhibitors, What the Emergency Physician Needs to Know: A Narrative Review

Détails

Ressource 1Télécharger: 34068655_BIB_D78919AA8999.pdf (251.86 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY 4.0
ID Serval
serval:BIB_D78919AA8999
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
SGLT2 Inhibitors, What the Emergency Physician Needs to Know: A Narrative Review
Périodique
Journal of Clinical Medicine
Auteur⸱e⸱s
Lu Henri, Lu Hortense, Kosinski Christophe, Wojtusciszyn Anne, Zanchi Anne, Carron Pierre-Nicolas, Müller Martin, Meyer Philippe, Martin Jehan, Muller Olivier, Hullin Roger
ISSN
2077-0383
Statut éditorial
Publié
Date de publication
10/05/2021
Volume
10
Numéro
9
Pages
2036
Langue
anglais
Résumé
Canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin belong to a class of antidiabetic treatments referred to as sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors, or SGLT2is). SGLT2is are currently indicated in North America and in Europe in type 2 diabetes mellitus, especially in patients with cardiovascular (CV) disease, high CV risk, heart failure, or renal disease. In Europe, dapagliflozin is also approved as an adjunct to insulin in patients with type 1 diabetes mellitus. New data provide evidence for benefits in heart failure with reduced ejection fraction and chronic kidney disease, including in patients without diabetes. The use of SGLT2is is expected to increase, suggesting that a growing number of patients will present to the emergency departments with these drugs. Most common adverse events are easily treatable, including mild genitourinary infections and conditions related to volume depletion. However, attention must be paid to some potentially serious adverse events, such as hypoglycemia (when combined with insulin or insulin secretagogues), lower limb ischemia, and diabetic ketoacidosis. We provide an up-to-date practical guide highlighting important elements on the adverse effects of SGLT2is and their handling in some frequently encountered clinical situations such as acute heart failure and decompensated diabetes.
Mots-clé
diabetes, heart failure, renal, guidelines
Web of science
Open Access
Oui
Création de la notice
28/05/2021 16:59
Dernière modification de la notice
12/01/2022 7:13
Données d'usage